Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C. ( armaceuticals Inc Lisa Conte Chi...)

HOME >> MEDICINE >> TECHNOLOGY

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C.

armaceuticals, Inc Lisa Conte, Chief Executive Officer (001) + 650 616 1902 Charles Thompson, Chief Financial Officer (001) + 650 616 1903 Buchanan Communications 020 7466 5000 Tim Anderson, Mary-Jane Johnson Russo Partners, LLC (001) + 619 814 3510 Greg Geissman

D-IBS

Irritable Bowel Syndrome ("IBS") is characterized by a constellation of gastro intestinal symptoms including diarrhea, constipation (or alternation of the two), urgency, and abdominal pain. IBS may affect up to 20 percent of the population in the US (estimates range from 15-20 percent; of whom 70 percent are women). More than 60 percent of the affected patients are managing either diarrhea predominant IBS ("D-IBS") or alternating IBS.

IBS ranks second only to the common cold as a cause of lost work time in the U.S. In addition, the disease accounts for approximately 3 million physician visits in the U.S. each year, costing the U.S. economy an estimated $30 billion annually. The global market could be over $15 billion for a safe and effective D-IBS product.

About Trine

Trine has licensed the worldwide development and commercialization rights to crofelemer for the indication of diarrhea predominant Irritable Bowel Syndrome (IBS), in exchange for a profit split with Napo on sales of the product for that indication. Additionally, Trine has the commercialization rights to CRO-HIV in North America in exchange for a 50 percent profit split.

Trine is a venture capital-backed firm based in Newton, Mass. Trine is currently conducting a Phase 2b study of crofelemer for diarrhoea-predominant- IBS.

About Napo

Napo Pharmaceuticals Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001 and is based in South San Francisco, Calif., w
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Post Your Comments:

( armaceuticals Inc Lisa Conte Chi...)Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C.,Health